Published in Neuropsychiatr Dis Treat on August 20, 2012
E2022 Patch Formulation Multiple Dose Study | NCT01450839
E2022 Patch Formulation Single Dose Phase I Study | NCT01253434
Effect of backing films on the transdermal delivery of donepezil from patches. AAPS PharmSciTech (2014) 0.77
Biopolymer-based transdermal films of donepezil as an alternative delivery approach in Alzheimer's disease treatment. AAPS PharmSciTech (2014) 0.75
Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug Des Devel Ther (2015) 0.75
A Randomized, Crossover, Single-Dose Bioequivalence Study of Two Extended-Release Tablets of Donepezil 23 mg in Healthy Human Volunteers under Fasting and Fed States. Sci Pharm (2013) 0.75
Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study. Pharm Res (2017) 0.75
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology (1998) 7.27
The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol (2000) 2.26
Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther (2010) 2.19
Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology (2007) 1.43
Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract (2009) 1.19
In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci (2001) 1.12
Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr (1997) 1.11
Donepezil: a review of its use in Alzheimer's disease. Drugs Aging (2000) 1.11
Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs (2009) 1.05
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol (2011) 1.01
Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology (2006) 1.01
Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv (2011) 0.97
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin (2010) 0.93
Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging (2006) 0.93
Delivering drugs by the transdermal route: review and comment. Skin Res Technol (2008) 0.93
Rationale for transdermal drug administration in Alzheimer disease. Neurology (2007) 0.93
Donepezil: an update. Expert Opin Pharmacother (2007) 0.91
Cholinesterase inhibitors stabilize Alzheimer's disease. Ann N Y Acad Sci (2000) 0.89
Effect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluation. Int J Pharm (2011) 0.87
Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord (2004) 0.85
Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects. Drugs Aging (2008) 0.83
Realistic expectations for the management of Alzheimer's disease. Eur Neuropsychopharmacol (1999) 0.80
Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging (1999) 0.80
Improvement of microemulsion electrokinetic chromatography for measuring octanol-water partition coefficients. Electrophoresis (2008) 0.80
New drugs for Alzheimer's disease in Japan. Psychiatry Clin Neurosci (2011) 0.79
Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes. Rapid Commun Mass Spectrom (2006) 0.79
A panoramic view of gene expression in the human kidney. Proc Natl Acad Sci U S A (2003) 1.72
Prodrug approach for increasing cellular glutathione levels. Molecules (2010) 1.01
Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. Blood (2010) 0.98
Dopaminergic system modulation, behavioral changes, and oxidative stress after neonatal administration of pyrethroids. Toxicology (2006) 0.97
Potential antibacterial activity of carvacrol-loaded poly(DL-lactide-co-glycolide) (PLGA) nanoparticles against microbial biofilm. Int J Mol Sci (2011) 0.87
Effects of early life permethrin exposure on spatial working memory and on monoamine levels in different brain areas of pre-senescent rats. Toxicology (2012) 0.85
Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease. Eur J Pharm Sci (2013) 0.84
Ibuprofen and glutathione conjugate as a potential therapeutic agent for treating Alzheimer's disease. Arch Pharm (Weinheim) (2010) 0.83
Temporal expression of agrB, cidA, and alsS in the early development of Staphylococcus aureus UAMS-1 biofilm formation and the structural role of extracellular DNA and carbohydrates. Pathog Dis (2014) 0.82
Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties. J Med Chem (2007) 0.81
Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb/Akt intracellular signaling pathway in Alzheimer's disease rat model. Gerontology (2013) 0.81
(R)-α-lipoyl-glycyl-L-prolyl-L-glutamyl dimethyl ester codrug as a multifunctional agent with potential neuroprotective activities. ChemMedChem (2012) 0.81
Fucoidan promotes early step of cardiac differentiation from human embryonic stem cells and long-term maintenance of beating areas. Tissue Eng Part A (2014) 0.80
Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert. Neurosci Lett (2004) 0.80
Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. PLoS One (2013) 0.79
Effect of choline-containing phospholipids on brain cholinergic transporters in the rat. J Neurol Sci (2010) 0.79
Synthesis of a novel cyclic prodrug of S-allyl-glutathione able to attenuate LPS-induced ROS production through the inhibition of MAPK pathways in U937 cells. Mol Pharm (2014) 0.79
Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity. Arch Pharm (Weinheim) (2010) 0.79
A glutathione derivative with chelating and in vitro neuroprotective activities: synthesis, physicochemical properties, and biological evaluation. ChemMedChem (2013) 0.79
New L-dopa codrugs as potential antiparkinson agents. Arch Pharm (Weinheim) (2008) 0.78
Designing prodrugs for the treatment of Parkinson's disease. Expert Opin Drug Discov (2012) 0.78
New flurbiprofen derivatives: synthesis, membrane affinity and evaluation of in vitro effect on β-amyloid levels. Molecules (2013) 0.78
Neuroprotective effects of farnesene against hydrogen peroxide-induced neurotoxicity in vitro. Cell Mol Neurobiol (2013) 0.78
CNS delivery of L-dopa by a new hybrid glutathione-methionine peptidomimetic prodrug. Amino Acids (2010) 0.78
Transition state isosteres of the gamma-glutamyl peptide bond hydrolysis: synthesis and characterization of the psi (CH2NH) pseudopeptide analogue of glutathione. J Pept Sci (2004) 0.77
Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs. Bioorg Med Chem (2010) 0.77
Proline-glutamate chimeras in isopeptides. Synthesis and biological evaluation of conformationally restricted glutathione analogues. Bioorg Med Chem (2003) 0.76
Protective effects of cyclosativene on H2O 2-induced injury in cultured rat primary cerebral cortex cells. Cytotechnology (2014) 0.76
Novel imidazoline compounds as partial or full agonists of D2-like dopamine receptors inspired by I2-imidazoline binding sites ligand 2-BFI. Bioorg Med Chem (2010) 0.76
Surfactant hydrogels for the dispersion of carbon-nanotube-based catalysts. Chemistry (2013) 0.76
Synthesis and biological evaluation of GABA derivatives able to cross the blood-brain barrier in rats. Bioorg Med Chem Lett (2003) 0.76
Synthesis and biological evaluation of the disulfide form of the glutathione analogue gamma-(L-glutamyl)-L-cysteinyl-L-aspartyl-L-cysteine. Bioorg Chem (2003) 0.76
Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson's disease. J Med Chem (2009) 0.76
Aplasia cutis congenita, skull defect, brain heterotopia, and intestinal lymphangiectasia. Am J Med Genet A (2005) 0.75
Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain. CNS Neurol Disord Drug Targets (2013) 0.75
NOS-mediated morphological and molecular modifications in rats infused with Aβ (1-40), as a model of Alzheimer's disease, in response to a new lipophilic molecular combination codrug-1. Exp Gerontol (2010) 0.75
Synthesis of novel 4-aryl-1,2,3,4-tetrahydroisoquinolines as probes for dopamine receptor ligands. Med Chem (2012) 0.75